589 related articles for article (PubMed ID: 23191934)
21. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support.
Paul B; Trovato JA; Thompson J; Badros AZ; Goloubeva O
J Oncol Pharm Pract; 2010 Mar; 16(1):45-51. PubMed ID: 19525301
[TBL] [Abstract][Full Text] [Related]
22. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
23. Aprepitant for the management of refractory emesis in a patient with a small bowel carcinoid tumor.
Kyeremateng S; Boland JW
J Pain Palliat Care Pharmacother; 2014 Jun; 28(2):135-7. PubMed ID: 24833205
[TBL] [Abstract][Full Text] [Related]
24. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
Gralla RJ; de Wit R; Herrstedt J; Carides AD; Ianus J; Guoguang-Ma J; Evans JK; Horgan KJ
Cancer; 2005 Aug; 104(4):864-8. PubMed ID: 15973669
[TBL] [Abstract][Full Text] [Related]
25. Aprepitant for chemotherapy-induced nausea and vomiting.
Flemm LA
Clin J Oncol Nurs; 2004 Jun; 8(3):303-6. PubMed ID: 15208824
[TBL] [Abstract][Full Text] [Related]
26. Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Hargreaves R; Ferreira JC; Hughes D; Brands J; Hale J; Mattson B; Mills S
Ann N Y Acad Sci; 2011 Mar; 1222():40-8. PubMed ID: 21434941
[TBL] [Abstract][Full Text] [Related]
27. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.
Massaro AM; Lenz KL
Ann Pharmacother; 2005 Jan; 39(1):77-85. PubMed ID: 15562136
[TBL] [Abstract][Full Text] [Related]
28. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
Albany C; Brames MJ; Fausel C; Johnson CS; Picus J; Einhorn LH
J Clin Oncol; 2012 Nov; 30(32):3998-4003. PubMed ID: 22915652
[TBL] [Abstract][Full Text] [Related]
29. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
Herrstedt J
Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
[TBL] [Abstract][Full Text] [Related]
30. A case of severe, refractory diabetic gastroparesis managed by prolonged use of aprepitant.
Chong K; Dhatariya K
Nat Rev Endocrinol; 2009 May; 5(5):285-8. PubMed ID: 19444262
[TBL] [Abstract][Full Text] [Related]
31. The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis.
Soykan I; Sarosiek I; McCallum RW
Am J Gastroenterol; 1997 Jun; 92(6):976-80. PubMed ID: 9177513
[TBL] [Abstract][Full Text] [Related]
32. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.
Sankhala KK; Pandya DM; Sarantopoulos J; Soefje SA; Giles FJ; Chawla SP
Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1607-14. PubMed ID: 19929449
[TBL] [Abstract][Full Text] [Related]
33. Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery.
Diemunsch P; Gan TJ; Philip BK; Girao MJ; Eberhart L; Irwin MG; Pueyo J; Chelly JE; Carides AD; Reiss T; Evans JK; Lawson FC;
Br J Anaesth; 2007 Aug; 99(2):202-11. PubMed ID: 17540667
[TBL] [Abstract][Full Text] [Related]
34. No more than necessary: safety and efficacy of low-dose promethazine.
Moser JD; Caldwell JB; Rhule FJ
Ann Pharmacother; 2006 Jan; 40(1):45-8. PubMed ID: 16352779
[TBL] [Abstract][Full Text] [Related]
35. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Grunberg S; Chua D; Maru A; Dinis J; DeVandry S; Boice JA; Hardwick JS; Beckford E; Taylor A; Carides A; Roila F; Herrstedt J
J Clin Oncol; 2011 Apr; 29(11):1495-501. PubMed ID: 21383291
[TBL] [Abstract][Full Text] [Related]
36. Integrating aprepitant and palonosetron into clinical practice: a role for the new antiemetics.
Viale PH
Clin J Oncol Nurs; 2005 Feb; 9(1):77-84. PubMed ID: 15751501
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F
J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996
[TBL] [Abstract][Full Text] [Related]
38. Granisetron: an update on its clinical use in the management of nausea and vomiting.
Aapro M
Oncologist; 2004; 9(6):673-86. PubMed ID: 15561811
[TBL] [Abstract][Full Text] [Related]
39. Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone.
Oechsle K; Müller MR; Hartmann JT; Kanz L; Bokemeyer C
Onkologie; 2006 Dec; 29(12):557-61. PubMed ID: 17202825
[TBL] [Abstract][Full Text] [Related]
40. Aprepitant for the management of nausea with inpatient IV dihydroergotamine.
Chou DE; Tso AR; Goadsby PJ
Neurology; 2016 Oct; 87(15):1613-1616. PubMed ID: 27629088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]